Boston nonprofit tackling 'superbugs' gets $52M from Gates foundation, U.K.
An accelerator program based at Boston University that funds the development of potential life-saving antibacterial drugs will receive up to $52 million from the U.K. government and the Bill& Melinda Gates Foundation.
The public-private partnership, called Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator — or CARB-X — announced the new funding on Tuesday. CARB-X said it has now raised more than $500 million since being launched in July 2016 by the U.S. Department of Health…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Max Stendahl Source Type: news
More News: Boston University | Funding | Government | Health Management | Infectious Diseases | Partnerships | Superbugs